# **Special Issue**

# Hepatitis B Virus Research in Italy: From Epidemiology to Treatment

## Message from the Guest Editor

More than fifty years since the discovery of the Australian antigen, hepatitis B virus (HBV) infection still represents a continuous challenge. Vaccination against HBV has represented a milestone for the control of this devastating disease, and there is optimism for new effective drugs for the treatment of hepatitis B. This Special Issue titled "Hepatitis B virus research in Italy: from epidemiology to treatment" will include a range of invited articles from Italian researchers. Italy was the first country to adopt a peculiar model of HB vaccination policy, which has nearly eliminated the acute infection. Moreover, important insights have been provided from Italian researchers on the epidemiology, prevention, natural history, diagnostics, and treatment of HBV infection. Articles in this Issue will deal with these topics with the collaboration of Italian researchers who have greatly improved the worldwide knowledge regarding HBV infection. Finally, an article will deal with major negative side effect of the existence of HBsAg(i.e. HDV), first discovered in Italy in the second half of the 1970s by Rizzetto et al.

#### **Guest Editor**

Dr. Tommaso Stroffolini Azienda Policlinico Umberto, Rome, Italy

#### Deadline for manuscript submissions

closed (30 June 2022)



# **Viruses**

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/104044

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





# Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

#### **Editor-in-Chief**

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

## **Journal Rank:**

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

